Bolt Biotherapeutics (BOLT) Misses Q2 EPS by 124c

Bolt Biotherapeutics (NASDAQ: BOLT) reported Q2 EPS of ($4.57), $1.24 worse than the analyst estimate of ($3.33). Revenue for the quarter came in at $5 thousand versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on Bolt Biotherapeutics (BOLT) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49